Boston, USA-based biotech start-up Kojin Therapeutics has announced the appointment of Harvey Berger as its new chairman, president and chief executive (CEO).
A biotech-industry veteran, Dr Berger is an experienced physician-scientist and entrepreneur, who brings over 35 years of global research and development (R&D), corporate, and commercial leadership experience to Kojin. He founded Ariad Pharmaceuticals and led the company from a start-up to a fully integrated global oncology company.
In this and other leadership roles, Dr Berger spearheaded the development and approval of six innovative, breakthrough medicines for patients with cancer, cardiovascular disease, and autoimmune disease, as well as a cancer-diagnostic blood test.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze